Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer. Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its...
Emerging JANX007 data demonstrated substantial clinical activity in 5L mCRPC patients, supporting clinical development plan directed at pre-PLUVICTO® 2L / 3L patients In 16 patients JANX007...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.35 | 4.30797433547 | 54.55 | 59.72 | 54.2 | 764526 | 56.70733982 | CS |
4 | 10.77 | 23.347062649 | 46.13 | 71.71 | 40.0183 | 1750609 | 59.70373427 | CS |
12 | 13.53 | 31.1966797325 | 43.37 | 71.71 | 40.0183 | 992328 | 55.62027153 | CS |
26 | 15.71 | 38.1403253217 | 41.19 | 71.71 | 34.5125 | 759068 | 50.89103543 | CS |
52 | 46.31 | 437.299338999 | 10.59 | 71.71 | 7.79 | 767433 | 48.14090043 | CS |
156 | 34.87 | 158.284157966 | 22.03 | 71.71 | 5.65 | 319571 | 41.18849137 | CS |
260 | 22.9 | 67.3529411765 | 34 | 71.71 | 5.65 | 300211 | 39.62917678 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.